Orencia (abatacept) — United Healthcare

Initial criteria

• Diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis
• AND Patient is not receiving Orencia in combination with another targeted immunomodulator [e.g., Enbrel, Cimzia, Simponi, adalimumab, Xeljanz, Olumiant, Rinvoq]
• AND Prescribed by or in consultation with a rheumatologist

Reauthorization criteria

• Documentation of positive clinical response to Orencia therapy
• AND Patient is not receiving Orencia in combination with another targeted immunomodulator [e.g., Enbrel, Cimzia, Simponi, adalimumab, Xeljanz, Olumiant, Rinvoq]

Approval duration

12 months